NEW YORK, May 16, 2013 /PRNewswire/ -- Developers of a pill bottle that wirelessly transmits data, measures medication and sends patient reminders have emerged as grand prize winners in the Healthcare Innovation World Cup, the international diabetes innovation challenge funded by Boehringer Ingelheim and organized by HITLAB.
Winning team members Josh Stein , John Langhauser and Mike Morena of Team AdhereTech from the United States will receive $50,000 in prize money. They earned the top spot by demonstrating the exceptional impact, innovation, feasibility and financial sustainability of their idea, and for engaging with community members via social media.
AdhereTech received its honors at the Healthcare Innovation World Cup finals event on Friday, May 10 at the German Center for Research and Innovation in New York City. Judges selected Team IITKgp for second place, Team SmartSense for third place, and Team EndoGoal as the fourth-place finalist.
First-place AdhereTech has created wireless pill bottles to help improve medication adherence. According to AdhereTech, the bottles measure the exact number of pills in the bottle in real-time, wirelessly send this HIPAA-compliant data into the cloud, and remind patients to take their medication via automated phone call or text message. The devices also record and send adherence data with an unprecedented level of granularity. This summer, AdhereTech, which is based in New York, NY, will begin a trial with The Walter Reed Army Medical Center to test its full-service solution for type 2 diabetes patients. According to Josh Stein , CEO of AdhereTech, there are both issued patents and patents pending for the devices. The company has secured funding, and is actively seeking additional investors. Visit www.adheretech.com for more information.
"We are impressed with AdhereTech's prototype and the feasibility of their business model, and believe the solution has merit in supporting medication adherence," said Klaus Wilgenbus, SVP, PM business development and licensing strategy at Boehringer Ingelheim and Healthcare Innovation World Cup judge. "All of the finalists demonstrated outstanding quality and ingenuity in developing their solutions. It is evident that they are committed to creating innovations with the potential to make a real difference in the lives of people with diabetes and their families."
The three other finalists were:
"Considering the caliber of these finalists – as well as many other participants in this competition – the future of diabetes innovation is exceptionally bright. We anticipate big achievements for all four finalists, and are excited to follow their trajectories in the healthcare industry," said Cole Manship , director of the Healthcare Innovation World Cup and manager of new programs and initiatives at HITLAB. "We hope this competition serves as a solid platform for their ongoing success."
All four teams received $2,500 each for reaching the final round of the competition. Overall, more than 100 teams representing 20 countries around the globe submitted diabetes innovations for the Healthcare Innovation World Cup, which awarded a total $75,000 in prizes to semifinalists and finalists. For more information about the competition and judges, visit www.healthcareinnovationworldcup.com.
About the Healthcare Innovation World Cup
The Healthcare Innovation World Cup challenges entrepreneurs and innovators in healthcare and information technology to tackle global public health issues. In 2013, the competition invited participants worldwide to propose solutions for improving diabetes prevention and management, offering $75,000 in total prize money and opportunities to showcase their work. www.healthcareinnovationworldcup.com
HITLAB is a cross-disciplinary public health teaching and research organization that studies and educates others about the impact of healthcare information and communications technology on public health. Based in New York, NY, the Lab's team includes faculty, scientists, research scholars and students from top universities around the world. www.hitlab.org
About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavours.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.
For more information please visit www.boehringer-ingelheim.com
The German Center for Research and Innovation provides information and support for the realization of cooperative and collaborative projects between North America and Germany. With the goal of enhancing communication on the critical challenges of the 21st century, GCRI hosts a wide range of events from lectures and exhibitions to workshops and science dinners. Opened in February 2010, GCRI was created as a cornerstone of the German government's initiative to internationalize science and research and is one of five centers worldwide. www.germaninnovation.org
+1 (212) 543-0100
Boehringer Ingelheim GmbH
+49 (6132) 77-2091
|SOURCE HITLAB; Boehringer Ingelheim GmbH|
Copyright©2012 PR Newswire.
All rights reserved